Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06158412
Status:
RECRUITING
Last Update Posted:
2023-12-11
First Post:
2023-11-22
Brief Title:
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of RefractoryRelapsed Multiple Myeloma
Sponsor:
The First Affiliated Hospital of Xiamen University
Organization:
The First Affiliated Hospital of Xiamen University
Study Overview
Official Title:
A Single-center Prospective Single-arm Clinical Study of All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of RefractoryRelapsed Multiple Myeloma MM
Status:
RECRUITING
Status Verified Date:
2023-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To investigate the safety and efficacy of the ATRA combined with the KPD regimen in patients with refractory relapsed multiple myeloma
Detailed Description:
This is an open-label clinical trial study that aims to evaluate the efficacy eg Complete response Overall Survival Progression Free Survival and adverse effects of Trans-Retinoic acid ATRA combined with the KPD regimen in patients with refractory relapsed multiple myeloma
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None